News Detail

20 Dec 2021 16:45:00
SET News :SET contributes THB 40 million to locally developed ChulaCov19 & Baiya vaccine projects
Full Detailed News
Download Full Detailed News
                                                                     JOINT RELEASE
                                                    SET News 104 /2021
                                                      December 20, 2021

SET contributes THB 40 million to locally developed ChulaCov19 & Baiya vaccine 

BANGKOK, December 20, 2021 - The Stock Exchange of Thailand (SET) has donated  
THB 40 million (approx. USD 1.20 million) to support two development projects by
Thai medical teams and experts on Covid-19 vaccine comprising 1) Baiya vaccine
by the Faculty of Pharmaceutical Sciences, Chulalongkorn University, and 2)
ChulaCov19 by the Faculty of Medicine, Chulalongkorn University and
Chulalongkorn Memorial Hospital - the Thai Red Cross Society, in line with the
government's policy to help speed up the progress of research and development
(R&D) of the Thai vaccines to success.

SET President Pakorn Peetathawatchai said that even though the COVID-19 
situation in Thailand has improved, it is still necessary to ensure that Thais
are immune to the virus in the long run. Having vaccine R&D and innovations in
Thailand by the Thai teams will help tackle the situations with less budget than
importing them from abroad.  SET aims to play a part in helping people and
society by donating  THB 40 million for the development of both projects which
need a lot of funding. The donation is in accordance with SET's intention to
promote Thai innovations that can lead to tangible results, and the vaccine
development projects are also in line with SET's vision "To Make the Capital
Market 'Work' for Everyone".

CU Enterprise Foundation Board Makorn Phongthanaprueks said that Baiya vaccine 
by Baiya Phytopharm Co., Ltd. is Thailand's first protein subunit vaccine from
Nicotiana benthamiana leaves researched and developed by Assoc. Prof. Dr.
Waranyoo Phoolcharoen and Asst. Prof. Dr. Suthira Taychakhoonavudh, lecturers at
the Faculty of Pharmaceutical Sciences, Chulalongkorn University. The Thai Food
and Drug Administration (FDA) has approved to produce the vaccine for human
trials. The Baiya vaccine production covers from upstream to downstream
processes starting from the pilot plant to produce plant-based vaccines and
biologics at Baiya's facility at Chulalongkorn University, before sending to
KinGen Biotech Co., Ltd. for purification process. The vaccine will then be
mixed and bottled at Queen Saovabha Memorial Institute, the Thai Red Cross
Society. The vaccine is currently in the first phase of clinical trial which
started opening for volunteer application from September 2021All volunteers have
received the full second dose of the vaccine and preliminary results showed
that the vaccine safety is satisfied and it is under process to further analyze
information in other aspects. The company stands ready to study and develop the
next generation of the vaccine which has effectiveness against variants.

Dean of Faculty of Medicine Assoc. Prof. Chanchai Sittipunt said that 
preliminary results of phase 1 and 2 of human trials of ChulaCov19 proved that
Thailand's home-grown mRNA vaccine is safe and can boost immunity to high level
which is on par with the Pfizer BioNTech while being even better than
AstraZeneca and Sinovac vaccines. The outstanding feature is that it generates
much higher protection against the original strain of Covid-19. This high
antibody response is also capable of inhibiting transmission of all four
strains: Alpha, Beta, Gamma and Delta.

Chula Vaccine Research Center together with Bionet Asia Co., Ltd. has produced 
30,000 vaccine doses for the 3rd phase of human trials. The trial vaccines have
been completely bottled and are now under quality and effectiveness inspection
by the FDA to ensure that their quality meets the FDA and the international
standards. After the FDA approval, the vaccine will be tested on 3,750
volunteers around January of 2022. If they are safe and can boost the
volunteers' immunity to Pfizer's level, the research and development team will
register with the FDA for emergency use. The team is thankful to SET for the
research support which will further benefit the innovation and development for
efficiency and excellence.

SET and the SET Foundation has been supporting and contributing over THB 112 
million of donations through various hospitals, organizations, foundations as
well as charitable organizations and volunteers  to ease the impact of Covid-19
pandemic on people and those affected by the spread this year, to benefit the
communities, society and the public during these difficult times until the
situation will be improved.